Virginia Retirement Systems ET AL Sells 26,600 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Virginia Retirement Systems ET AL lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 20.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 105,000 shares of the biopharmaceutical company’s stock after selling 26,600 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Gilead Sciences were worth $6,655,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Advisors Preferred LLC purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $26,000. First Financial Corp IN grew its stake in Gilead Sciences by 286.4% in the 3rd quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 401 shares in the last quarter. Legacy Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $37,000. Evolution Wealth Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $46,000. Finally, Motco grew its stake in Gilead Sciences by 213.6% in the 2nd quarter. Motco now owns 690 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 470 shares in the last quarter. 79.67% of the stock is currently owned by institutional investors.

NASDAQ:GILD traded down $0.86 during midday trading on Thursday, hitting $65.72. The company had a trading volume of 303,685 shares, compared to its average volume of 5,765,219. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $72.90. The stock’s fifty day moving average price is $64.53 and its 200-day moving average price is $65.35. The company has a market capitalization of $83.31 billion, a PE ratio of 10.70, a P/E/G ratio of 2.99 and a beta of 1.10. The company has a quick ratio of 3.67, a current ratio of 3.76 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The company had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same period in the previous year, the business earned $1.91 earnings per share. The firm’s quarterly revenue was down 2.8% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 6.68 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 3.83%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

A number of research analysts recently weighed in on GILD shares. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Monday, July 15th. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $68.00 to $88.00 in a research note on Monday, July 15th. Raymond James set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, August 23rd. Cantor Fitzgerald set a $88.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Jefferies Financial Group set a $95.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus price target of $81.36.

In related news, EVP Brett A. Pletcher sold 608 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $64.35, for a total value of $39,124.80. Following the completion of the transaction, the executive vice president now directly owns 27,198 shares in the company, valued at $1,750,191.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Olsen Per Wold sold 4,908 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $63.91, for a total transaction of $313,670.28. Following the completion of the transaction, the director now owns 102,762 shares of the company’s stock, valued at $6,567,519.42. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: Risk Tolerance

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.